anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To prepare an oil-in-water type emulsified composition dispersely stable with passage of time by dissolving hydrogenated lecithin, stevia and polyhydric alcohol by heating at a temperature equal to or higher than the melting point of lecithin and thereafter gradually adding oil thereto under agitation. CONSTITUTION:Polyhydric alcohol, hydrogenated lecithin and stevia are dissolved together by heating at a temperature equal to or higher than the melting point of hydrogenated lecithin, and the oil dissolved by preheating is gradually added thereto under agitation, thereby preparing an emulsified composition. By adding water to the resulting oil-in-polyhydric alcohol type composition, an oil-in-water type emulsified composition supremely excellent in stability can be obtained. It is preferable that the ratio of the dehydrogenated lecithin to the stevia is 1:9-9:1 by weight and that the concentration of the polyhydric alcohol solution including the hydrogenated lecithin and stevia is 1-75wt.%. Liquid paraffin, mink oil, cetyl isooctanoate, etc. are available as the additive oil.
The present disclosure provides small hairpin nucleic acid molecules capable of stimulating interferon production. The nucleic acid molecules of the present disclosure has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises at least one 5′-triphosphate and/or at least one 5′-diphosphate. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection, and/or ameliorating, minimizing, reversing, and/or preventing persistent SARS-CoV-2 viral infection, and/or minimizing or preventing SARS-CoV-2 viral infection-derived mortality and/or lethality, in a subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in a tumor-bearing subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in an immune-compromised and/or immunodeficient subject.
A functional composition produced according to the present invention has excellent function improvement and immunity enhancement effects. In addition, the functional composition has an excellent DPPH free radical scavenging activity to have an antioxidant effect and suppresses the generation of NO and the generation of inflammatory cytokines to have an anti-inflammatory effect. Also, the functional composition suppresses platelet aggregation to have the effect of inhibiting the formation of blood clots and suppresses the constriction of blood vessels to have the effect of inducing vascular relaxation. In addition, the functional composition suppresses the increase in cholesterol to be recognized for effectiveness in reducing blood and liver lipids and has an antiviral effect, especially an infection-inhibiting effect against coronavirus. In addition, the composition of the present invention suppresses the generation of interleukin (IL)-6, IL-8, IL-1β, IL-4, and IL-13, which are cytokines expressed during an inflammatory reaction in human keratinocyte cell lines (HaCaT cells), suppresses the activity of MAPKs, suppresses the expression of TARC and MDC, which are a type of chemokine generated during an inflammatory reaction, and has the effect of regulating the expression of NF-κB and IκBα. The composition of the present invention has the function of activating or regenerating cells without causing any damage to internal organs such as kidneys, liver, and lungs.
NEW MATERIAL:A cyclopentene derivative shown by the formula I (R and R<1> are H, CH3, or C2H5). EXAMPLE:4-(2,2,3-Trimethylcyclopenta-3-en-1-yl)-2-butene-1-ol. USE:Useful as a modifier for imparting durable fragrance and flavor. Having fragrance and flavor like natural sandalwood, showing sweet, mild, and natural fragrance of good body. Useful as a fragrant component for various foods and drinks, cosmetic, health and hygiene, drugs, etc. Miscible well with other synthetic perfume, natural perfume, etc. PREPARATION:For example, 4-(2,2,3-trimethyl-cyclopenta-3-en-1-yl)-2-butenoic acid shown by the formula II is reacted with a reducing agent such as aluminum lithium hydroxide, etc. at about 0-80 deg.C in an organic solvent, to give the example compound in a compound shown by the formula.
The investigators will conduct a randomized controlled trial (RCT) to examine the effects of time-restricted eating as compared to the mediterranean diet. In time-restricted eating (TRE), participants will be asked to limit their food intake to a period of 10 hours per day. In the mediterranean diet, participants will be asked to follow a food plan that emphasizes vegetables, fruit, whole grains, and olive oil as central dietary components. The investigators aim to test both food plans as additions to standard medication approaches in bipolar disorder. Participants who are receiving medical treatment for bipolar disorder and who report at least some sleep or circadian problems will complete baseline measures and then will be randomly assigned to TRE or the mediterranean diet for 8 weeks, and then will complete measures of symptoms, Quality of Life, and possible treatment mechanisms at the end of treatment and at 3, 6 and 12 months after the intervention. If successful, this work will provide a novel, easily implemented and highly acceptable intervention for BD.
PURPOSE:A food for healthy eyes, consisting essentially of leaf part of a persimmon tree (Diospyros kaki Thunb.) and/or fruit of Psidium guajava L.). CONSTITUTION:A food for healthy eyes obtained by collecting leaves of a persimmon tree (Diospyros kaki Thunb.), washing the leaves with water, finely cutting the washed leaves to about 3cm width steaming or boiling the cut leaves, unfolding the leaves, drying the unfolded leaves, treating a fruit of Psidium guajava L. similarly to the leaves of the persimmon tree, steaming or boiling the fruit, heating or parching the fruit, fruit, rolling and twisting the fruit, repeating the rolling and twisting step, optionally air-drying the fruit or freeze- drying the fruit in the case of a flesh or fruit into freeze-dried powder and incorporating both components therein. The food has effect and action of smoothing the microcirculation, preventing the increase in blood pressure and blood sugar at the same time, expanding peripheral blood vessels of ocular part, removing blood and asthenopia, etc. The form of the food includes granule, tablet, refreshing drink, etc.
Stress is one of the more common reasons cited by addicts for continual drug use and relapse. Naltrexone treatment of opiate addicts suffers from high rates of drop-out and relapse. This may be a result of naltrexone's inability to reduce symptoms of stress during early recovery. Treatment approaches that target both drug-induced and stress-induced relapse may prove to be more beneficial than targeting drug-induced relapse alone. Lofexidine is a drug that reduces the physical symptoms of opiate withdrawal and may prove to have stress-reducing capabilities. The purpose of this study is to determine the maximal safe dose of lofexidine tolerated in naltrexone-treated opiate addicts and to find an optimal lofexidine induction schedule. The study will also assess any side effects that occur during a discontinuation phase of lofexidine.

This pilot study will last a total of 8 weeks. Recently detoxified opiate dependent participants who are eligible for naltrexone treatment will enter a 4-week single-blind dose tolerability phase, during which participants will receive naltrexone and 1 of 3 twice-daily lofexidine induction schedules. All participants will be required to remain in the clinic for 2 hours immediately following dosing in order to monitor vital signs and side effects. Study visits will occur three times each week, at which time naltrexone medication for self-administration will be handed out and participants will be evaluated in terms of tolerability to treatment. After the 4 weeks of treatment, a double-blind lofexidine detoxification phase using a 5-day taper will occur. Participants will be randomly assigned to one of two maintenance-taper schedules. The first group will undergo a 5-day tapering, followed by a placebo for three weeks, followed by a 5-day tapering during Week 4. Withdrawal symptoms and side effects will be evaluated.
Exercises will target bilateral 1) knee extensor, 2) ankle plantarflexor, and 3) elbow extensor muscles. Exercises will be dosed based on 1RM and individualized for each participant from a standardized exercise set. Progression will be based on 1) body position (supine, seated, standing), and 2) degree of resistance. Dosing will be re-assessed every 2 weeks and progressed as tolerated. Resistance will be provided by the Shuttle Mini-Press (Shuttle Systems), a portable resistance trainer that allows for precise dosing but is also adaptable to people with mobility limitations.
The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml of anti-dsDNA antibodies in his/her blood plasma or serum comprising administering a therapeutically effective amount of an immunomodulatory agent, such as an antagonist of Neutrokine-alpha. Additionally provided is a method of reducing the frequency and/or quantity of corticosteroid administration to patients. In preferred embodiments, the patient has systemic lupus erythematosus. Methods for determining if a lupus patient is responding to medical treatment are also provided. (UnD Lf0) :> 0) Oi. cooc co oz 0<0 (00 Al C 0 cUo Mhe 1/1
Participants from the long-term period of study NCT00559585 who enrolled in the ACP substudy switched to administration of subcutaneous (SC) abatacept via the ACP for the duration of the substudy. Abatacept was administered SC using the ACP by the participant or caregiver on Substudy Day 1 and at weekly intervals thereafter. The ACP was a pre-filled liquid product device delivering 125 mg abatacept/device (125 mg/mL).
Spinal anesthesia has a recognized use during labor and delivery. Bupivacaine hydrochloride, when administered properly, via the epidural route in doses 10 to 12 times the amount used in spinal anesthesia has been used for obstetrical analgesia and anesthesia without evidence of adverse effects on the fetus.

Maternal hypotension has resulted from regional anesthesia. Local anesthetics produce vasodilation by blocking sympathetic nerves. Elevating the patient’s legs and positioning her on her left side will help prevent decreases in blood pressure. The fetal heart rate also should be monitored continuously and electronic fetal monitoring is highly advisable.

It is extremely important to avoid aortocaval compression by the gravid uterus during administrations of regional block to parturients. To do this, the patient must be maintained in the left lateral decubitus position or a blanket roll or sandbag may be placed beneath the right hip and the gravid uterus displaced to the left.

Spinal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts. Spinal anesthesia has also been reported to prolong the second stage of labor by removing the parturient’s reflex urge to bear down or by interfering with motor function. The use of obstetrical anesthesia may increase the need for forceps assistance.

The use of some local anesthetic drug products during labor and delivery may be followed by diminished muscle strength and tone for the first day or two of life. This has not been reported with bupivacaine.

There have been reports of cardiac arrest during use of Bupivacaine Hydrochloride in Dextrose Injection, USP 0.75% solution for epidural anesthesia in obstetrical patients. The package insert for Bupivacaine Hydrochloride in Dextrose Injection, USP hydrochloride for epidural, nerve block, etc., has a more complete discussion of preparation for, and management of, this problem. These cases are compatible with systemic toxicity following unintended intravascular injection of the much larger doses recommended for epidural anesthesia and have not occurred within the dose range of bupivacaine hydrochloride 0.75% recommended for spinal anesthesia in obstetrics. The 0.75% concentration of Bupivacaine Hydrochloride in Dextrose Injection, USP is therefore not recommended for obstetrical epidural anesthesia.

Bupivacaine Hydrochloride in Dextrose Injection, USP is recommended for spinal anesthesia in obstetrics.
Will involve testing archived FFPE clot samples from confirmed pancreatic adenocarcinoma patients since 2014 (Approximately 20 cases per year). KRAS testing will be performed using the Idylla platform to establish if there is a KRAS codon 12 mutation present in 94% percent of the cases reported at RCHT. Patients will have consented to the use of their tissue at the time of procedure. Prospectively new patients diagnosed with pancreatic adenocarcinoma will have KRAS testing on the FFPE clot made as part of the routine diagnostic work up and KRAS testing on the LBC sample.
This study is a multicenter 2:1 randomized nonblinded phase II interventional clinical trial in liver transplant recipients. The primary objective is to determine the safety, efficacy, and tolerability of tacrolimus minimization and eventual withdrawal in conjunction with everolimus monotherapy to preserve renal function. Study subjects will undergo first reduction of tacrolimus with the addition of everolimus. If everolimus is tolerated, subjects will be randomized 2:1 into one of two interventional arms. The first interventional arm will under a stepwise reduction of tacrolimus and be on everolimus monotherapy for the remainder of the study. The second interventional arm will remain on the initial reduced tacrolimus dose and everolimus. If subjects prior to randomization are unable to tolerate everolimus, these subjects will be placed in the observational group. These subjects will stop taking everolimus and resume their immunosuppression therapy prior to study enrollment.
PURPOSE: Surgical management of ovarian masses in girls still challenging. The aim of the study is to report an 8-year experience in managing children with ovarian masses, and to demonstrate the advantages and the limitations of laparoscopy for such lesions.
METHODS: Data of girls aged less than 18 years operated because of an ovarian mass between January 2015 and February 2023 were retrospectively reviewed. Patients were divided into two groups: group A including children operated by laparoscopy, and Group B of patients who underwent open surgery.
RESULTS: Eighty-eight children were enrolled. Laparoscopy was performed in 56 patients (63.6%). Group A patients had smaller tumor size (53.6±38.5 vs. 122.2±75.4 mm, P<0.0001), shorter operative time (50.4±20.3 vs. 71.5±36.5 min, P = 0.004), reduced length of hospital stay (1.4±1.1 vs. 3±2.3 days, P<0.0001), and absence of postoperative complications. Only 3 cases (5.7%) of recurrence were seen exclusively within patients followed for benign tumors during a mean follow-up period of 4.6±3 years.
CONCLUSION: Laparoscopy should be done in benign ovarian lesions or/and if a torsion is seen. For tumors at high risk of malignancy, laparoscopy can be performed to establish a clear macroscopic diagnosis, for staging of the disease, and resection of small tumors. Conversion to open surgery is indicated in case of doubt.
Functional evaluation of the mandible was performed by measuring active mandibular movements (Fig 1). For mandibular depression, participants were asked to open their mouths as much as they could without pain. The distance between central incisors of the mandibular row of teeth and the maxillary row of the obturator was recorded. For mandible protrusion, they pushed their lower jaws forward as far as they could and the distance between the upper and lower jaws were recorded. For mandibular deviation, participants pushed their lower jaws first left and then right, and lateral mandibular excursions were measured from upper incisal midline to lower midline. All measurements were performed with the help of a 20-cm ruler and recorded in cm 16.

Facial anthropometry was measured on photograph. A digital camera mounted on a tripod at 110 centimeters in height and a distance of 100 centimeters was used to take photographs 17. Participants' position was standardized on a previously marked cross on the floor. Those who wear glasses were asked to remove the glasses, and the participants with long hair were asked to tie their hair from the top. They were asked to assume a relaxed standing position when the photographs were taken. A small white square sticker 2 cm × 2 cm was placed on the forehead and on the flat surfaces of the right and left cheeks, with the camera lens perpendicular to the square. The purpose of the sticker was to be able to express linear measurements as centimeters rather than pixels while measuring the 3 sides of facial anthropometric landmarks using the Image J program 18. All participants were photographed at front and right and left sides. The measured anthropometric variables were as follows: physiognomic face height, morphological face height, lower face height, face width, mandible width, right upper facial depth, left upper facial depth, right lower facial depth, left lower facial depth, right midfacial depth, left midfacial depth, biocular width, cheek width (distance between inferior insertion of ear), and mouth width. Landmarks are shown and measured variables are defined in Fig 2 19,20. Face golden ratio was used to determine face shape and facial index was used for face phenotype. Face golden ratio was the ratio of physiognomic facial height to the face width, and facial index was the ratio of morphological face height and maximum face width.
Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients.
Herein, the synthesis of N,Ndiallyl morpholinium monomers and polymerization of the same to form rings at high yield and purity are explained. The process involves the synthesis of N,Ndiallyl morpholinium bromide and chloride and subsequently partially or completely exchanging their anions with borate, p-toluenesulfonate, oleate, and acetate anions. The cyclopolimerization of monomers yields water soluble polymers carrying quaternary ammonium groups in each repeated unit, whose aqueous solutions act as a bactericide solution. These solutions are advantageous in preparation of antibacterial formulations intended for domestic use. The polymer with bromide and borate anions is an efficient antibacterial which is able to kill “ Pseudomonas Aeruginosa ”, the hardest hospital bacterium to cope with, as well as various common bacteria. These formulations are suitable for producing bactericide wet wipes and forming abacterial surfaces and, when combined with air conditioners, generating bacteria free air.
PURPOSE: An oil-in-water cosmetic material for UV protection is provided to ensure freshness and lightness, and to block UV protection with waterproof property. CONSTITUTION: A cosmetic composition for UV protection contains a bead containing a UV absorber or a blocking agent. The composition also contains a high carbon number alcohol and fatty acid in a ratio of 4.5:1-5.5:1. The composition contains 1.0-5.0 wt% of the high carbon number alcohol and fatty acid and 1-5 wt% of the bead. The high carbon number alcohol is selected from a group consisting of benehyl alcohol, cetearyl alcohol, cetyl alcohol, and stearyl alcohol. The fatty acid is selected from a group consisting of stearic acid, benehic acid, and palmitic acid. The composition is a gel type.
Sepsis and multidrug resistance comprise a complex of factors attributable to mortality among intensive care unit (ICU) patients globally. Pathogens implicated in sepsis are diverse, and their virulence and drug resistance remain elusive. From a tertiary care hospital ICU in Uganda, we isolated a Citrobacter freundii strain RSM030 from a patient with sepsis and phenotypically tested it against a panel of 16 antibiotics including imipenem levofloxacin, cotrimoxazole and colistin, among others. We sequenced the organism's genome and integrated multilocus sequencing (MLST), PathogenFinder with Virulence Factor analyzer (VFanalyzer) to establish its pathogenic relevance. Thereafter, we combined antiSMASH and PRISM genome mining with molecular docking to predict biosynthetic gene clusters (BGCs), pathways, toxin structures and their potential targets in-silico. Finally, we coupled ResFinder with comprehensive antibiotic resistance database (CARD) to scrutinize the genomic antimicrobial resistance profile of the isolate. From PathogenFinder and MLST, this organism was confirmed to be a human pathogen (p = 0.843), sequence type (ST)150, whose virulence is determined by chromosomal type III secretion system (T3SS) (the injectosome) and plasmid-encoded type IV secretion system (T4SS), the enterobactin biosynthetic gene cluster and biofilm formation through the pgaABCD operon. Pathway and molecular docking analyses revealed that the shikimate pathway can generate a toxin targeting multiple host proteins including spectrin, detector of cytokinesis protein 2 (Dock2) and plasmalemma vesicle-associated protein (PLVAP), potentially distorting the host cell integrity. From phenotypic antibiotic testing, we found indeterminate results for amoxicillin/clavulanate and levofloxacin, with resistance to cotrimoxazole and colistin. Detailed genome analysis revealed chromosomal beta lactam resistance genes, i.e. blaCMY-79, blaCMY-116 and blaTEM-1B, along with multiple mutations of the lipopolysaccharide modifying operon genes PmrA/PmrB, pmrD, mgrA/mgrB and PhoP/PhoQ, conferring colistin resistance. From these findings, we infer that Citrobacter freundii strain RSM030 is implicated in sepsis and resistance to standard antibiotics, including colistin, the last resort.
In this group, children will receive a placebo intervention along with diet and physical activity recommendations according to the WHO guidelines. They will be followed for 16 weeks. During this period, patients will be contacted weekly to corroborate the consumption of the capsules and interrogation of adverse effects such as dyspepsia, gastrointestinal disturbances and headache. They will be scheduled monthly for capsule counting and interrogation of adverse effects.
Participants in control group will receive an exercise program consisted of upper and lower extremity strengthening and balance exercises.The exercises will be started as 8-10 repetitions and one set and the number of sets will be increased according to the progression of the patient. Exercises will be applied for 6 weeks, 5 days a week, for a total of 30 sessions, each session for 1 hour.